Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Workshop to Establish an International 7T Glioma Magnetic Resonance Spectroscopy Network (GlioMaRS-Net)

Workshop banner

Workshop times

Monday 16 November: 16:00-18:00 (UK London, GMT) 10:00-12:00 (UTC-6, Minnesota) 17:00-19:00 (UTC+1, Amsterdam)

Tuesday 17 November - Friday 20 November: 16:00-17:00 (UK London, GMT) 10:00-11:00 (UTC-6, Minnesota) 17:00-18:00 (UTC+1, Amsterdam)

Workshop background

Research into the role of ‘metabolic reprogramming’ and so-called ‘oncometabolites’ in cancer has seen a renaissance since the discovery that mutations in enzymes of the tricarboxylic acid (TCA) cycle can act as oncogenic drivers. Specifically, mutations in IDH1 or IDH2 and the resulting production of D-2-hydroxyglutarate (D2-HG) have come to define diffuse gliomas in young adults. This has opened up exciting new opportunities for noninvasive molecular glioma imaging with magnetic resonance spectroscopy (MRS) for diagnostics, trial recruitment and assessment of treatments. Further, a better understanding of the molecular mechanisms of mutation-specific metabolic reprogramming is likely to offer new drug targets.

These exciting developments have prompted us to convene an international workshop to explore how we could work together to drive forward progress in the field of glioma metabolomics for our patients.

Workshop goals

  • Find common ground on how MRS can contribute to ‘glioma precision medicine’ (and how it complements other imaging modalities)
  • Explore what is needed to build a multi-centre consortium (e.g. protocol / data sharing)
  • Identify scientific priorities at biochemical, cellular, tissue and whole brain imaging levels, and consider feasibility for integration of multimodal, multiscale data
  • Identify funding possibilities
  • Discuss options for writing a joint ‘perspectives’ paper about the potential of integrated MRS imaging in glioma precision medicine We encourage attendance by neurooncologists, neurosurgeons, biochemists and pathologists, in addition to those involved in MRS.

Workshop programme

Monday: 16:00-18:00 (UK London, GMT) 10:00-12:00 (UTC-6, Minnesota) 17:00-19:00 (UTC+1, Amsterdam)

Tuesday-Friday :16:00-17:00 (UK London, GMT) 10:00-11:00 (UTC-6, Minnesota) 17:00-18:00 (UTC+1, Amsterdam)

The following daily session times are shown in UK London (GMT) time

Monday 16 November 2020
Hosts: Olaf Ansorge, Jannie Wijnen and Uzay Emir

16:00-16:10 Welcome, Introductions and Review of Meeting Goals

16:10 – 17:40 Plenary session: “Current status of glioma precision medicine”

16:10: Molecular neuropathology and classification of gliomas
Olaf Ansorge, MD, Consultant neuropathologist and Director of the Academic Unit of Neuropathology, Nuffield Department of Clinical Neurosciences, Oxford

16:40: 'Radiogenomics – MRI and MRS in brain cancer”'
Alexander Lin, PhD, Director of the Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School

17:10: 'IDH-mutated gliomas: clinical challenges and opportunities'
Clark C Chen, MD, PhD, Lyle French Chair in Neurosurgery and Department Head, University of Minnesota

17:40 -17:50: Proposal for a consensus ‘viewpoint’ paper and invitation to contribute

17:50 – 18:00: Instructions for workshops and closure

Tuesday 17 November 2020
Host: Uzay Emir
Co-host: Jannie Wijnen

16:00 -17:00: How to do Radiomics? from data acquisition to sharing

  • Standardization of MRS protocols and analysis?
  • Integration of in vivo MRS with ex vivo tissue metabolomics and genomics
  • Data/method Sharing

Wednesday 18 November 2020
Hosts: Anja van der Kolk, Clark Chen

16:00-17:00: Clinical workflow and recruitment for clinical trials

  • Patient recruitment
  • Data sharing
  • Jurisdictions
  • Embedding in clinical workflow

Thursday 19 November 2020
Host: Olaf Ansorge
Co-host: Alex Lin

16:00-17:00: Funding & Engagement with external parties

  • Integration of in vivo MRS with other imaging modalities
  • From basic science to drug development and engagement with pharma
  • Engagement with MR vendors?
  • (International) funding possibilities

Organization team reconvenes after the sessions to prepare summaries for Friday

Friday 20 November 2020
Host: Jannie Wijnen
Cohost: Evita Wiegers

16:00 -16:30: Summary of main findings of workshop

16:30 - 17:00: Discussion and plan for the way forward

Olaf Ansorge
(on behalf of the organising committee)
Wellcome Centre for Integrative Neuroimaging,
Nuffield Department of Clinical Neurosciences,
University of Oxford, Oxford UK

For any questions, please contact: putiing GlioMaRS-Net workshop in the subject line